This study is testing two doses of an investigational implant called EC-104 (high dose: fluocinolone acetonide 0.14 mg; low dose: fluocinolone acetonide 0.092 mg) against a currently available treatment, Ozurdex® (dexamethasone intravitreal implant 0.7 mg). The goal is to see how safe and effective these treatments are for people with diabetic macular edema (DME), a swelling in the eye caused by diabetes, who haven't responded well to other treatments. Researchers are looking for about 75 participants who are at least 18 years old. The main goal is to check for safety and how well the treatments work over 24 weeks. The study is currently recruiting, but the exact status is unclear.

Study design

This is a randomized, masked Phase 2 study comparing three different treatments in about 75 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for ocular and systemic safety through Week 24.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.